Reference
1. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet . 2019;393(10169):364-376. doi:10.1016/S0140-6736(18)32112-3
2. Adachi JD, Ioannidis G, Pickard L, et al. The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int . 2003;14(11):895-904. doi:10.1007/s00198-003-1483-3
3. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med . 2014;370(5):412-420. doi:10.1056/NEJMoa1305224
4. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med . 2017;377(15):1417-1427. doi:10.1056/NEJMoa1708322
5. Kranenburg G, Bartstra JW, Weijmans M, et al. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis.Atherosclerosis . 2016;252:106-115. doi:10.1016/j.atherosclerosis.2016.06.039
6. Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int . 2013;24(1):271-277. doi:10.1007/s00198-012-2213-5
7. Metra M, Teerlink JR. Heart failure. Lancet . 2017;390(10106):1981-1995. doi:10.1016/S0140-6736(17)31071-1
8. Choi BG, Rha SW, Yoon SG, Choi CU, Lee MW, Kim SW. Association of major adverse cardiac events up to 5 years in patients with chest pain without significant coronary artery disease in the Korean population.J Am Heart Assoc . 2019;8(12):e010541. doi:10.1161/JAHA.118.010541
9. Emdin CA, Wong CX, Hsiao AJ, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ . 2016;352:h7013. doi:10.1136/bmj.h7013
10. Lewiecki EM, Blicharski T, Goemaere S, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab . 2018;103(9):3183-3193. doi:10.1210/jc.2017-02163
11. Brandenburg VM, Verhulst A, Babler A, D’Haese PC, Evenepoel P, Kaesler N. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant . 2019;34(3):408-414. doi:10.1093/ndt/gfy129
12. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension . 2001;37(4):1053-1059. doi:10.1161/01.hyp.37.4.1053
13. Hu G, Sarti C, Jousilahti P, et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke . 2005;36(12):2538-2543. doi:10.1161/01.STR.0000190894.30964.75
14. Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab . 2012;97(5):1737-1744. doi:10.1210/jc.2011-2958
15. Chang YC, Hsu BG, Liou HH, Lee CJ, Wang JH. Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients. BMC Cardiovasc Disord . 2018;18(1):214. doi:10.1186/s12872-018-0955-5
16. Cosman F, Peterson LR, Towler DA, Mitlak B, Wang Y, Cummings SR. Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE phase 3 trial. J Clin Endocrinol Metab . 2020;105(11):dgaa450. doi:10.1210/clinem/dgaa450
17. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2020 update. Endocr Pract . 2020;26(Suppl 1):1-46. doi:10.4158/GL-2020-0524SUPPL
18. Qu X, Huang X, Jin F, et al. Bone mineral density and all-cause, cardiovascular and stroke mortality: a meta-analysis of prospective cohort studies. Int J Cardiol . 2013;166(2):385-393. doi:10.1016/j.ijcard.2011.10.114
19. Tanaka M, Idei M, Sakaguchi H, et al. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan. Br J Clin Pharmacol . 2021;87(8):3279-3291. doi:10.1111/bcp.14749
20. Figueiras A, Herdeiro MT, Polónia J, Gestal-Otero JJ. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA . 2006;296(9):1086-1093. doi:10.1001/jama.296.9.1086